A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
NCT07468396
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
65
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
GLR2037
Sponsor
Gan & Lee Pharmaceuticals.